PBT434 is a potent, orally active, blood-brain barrier-permeable inhibitor of α-synuclein aggregation; it acts as an iron chelator and modulator of transcellular iron transport, inhibits iron-mediated redox activity and iron-induced α-synuclein aggregation, prevents loss of substantia nigra pars compacta (SNpc) neurons, and shows potential for research in Parkinson’s disease (PD).